Bli medlem
Bli medlem

Du är här

2020-05-29

Scandion Oncology A/S: Communique from the Annual General Meeting of Scandion Oncology A/S

On May 27th, 2020, the Annual General Meeting of Scandion Oncology A/S
("Scandion Oncology" or the "Company") was held. Below follows a
summary of the established decisions. All decisions were taken with
the required majority.

The Board of Directors report on the Company's business in the past
year

The general meeting took note of the Board of Directors report on the
Company's activities in 2019.

Presentation of the revised annual report for 2019 for approval

The general meeting unanimously adopted the audited annual report for
2019.

Decision to transfer the deficit for next year

The general meeting decided to transfer the deficit to the next year.

Election of members to the Board of Directors

The general meeting decided to elect Bo Rode Hansen as new Board
member and to re-elect Peter Høngård Andersen, Jørgen Vilhelm
Løvenørn Bardenfleth, Carl Arne Krister Borreback, Thomas Feldthus,
and Christian Vinding Thomsen to the Board of Directors until the
next Annual General Meeting.

Appointment of auditor

The general meeting decided that the Company's current auditor,
Deloitte is re-elected until the next Annual General Meeting.

Authorization for the Board of Directors to make one or more capital
increases

The general meeting decided to authorize the Board of Directors to
decide, at one or more occasions, a capital increase pursuant to
section 155 of the Danish Companies Act by offering the Company's
shares to the public at the Spotlight Stock Market.

Authorization for the Board of Directors to issue warrants

The Board of Directors proposed that the proposal was not transacted
at the general meeting but instead is transacted at a later general
meeting in the Company.

Voluntary arrangement for employee representation in the Company

The general meeting decided to adopt a voluntary arrangement for
employee representation in the Company.

For further information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com

Scandion Oncology A/S is a biotechnology company that addresses one of
the greatest challenges in modern oncology - the effective treatment
of cancer which contains chemotherapy-resistant cells or which has
developed resistance to a previously prescribed cancer-fighting drug.
In preclinical in vitro-studies SCO-101 restores chemotherapy
sensitivity in resistant cancer cells. Moreover, in animal studies,
the company's leading candidate drug, SCO-101, significantly enhances
the efficacy of certain standard cancer treatments when given in
combination. Scandion Oncology is now in clinical phase II trials
with its lead compound, SCO-101, in patients with
chemotherapy-resistant colorectal cancer. In addition to SCO-101 the
Company has two other drug candidates, SCO-201 and SCO-301. Scandion
Oncology was listed on Spotlight Stock Market, Sweden in November
2018.

-----------------------------------------------------------
https://news.cision.com/dk/scandion-oncology-a-s/r/communique-from-the-a...
https://mb.cision.com/Main/17596/3123425/1256155.pdf

Författare AktieTorget News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.